Secondary analysis of FOURIER (25 090 patients with atherosclerotic disease): low lipoprotein(a) was not associated with haemorrhagic stroke, bleeding, cancer or AF, but each 50 nmol/L lower was linked to incident diabetes (HR 1.05); evolocumab did not raise diabetes risk.
Secondary analysisn = 25,090
Gencer et al. Safety of low lipoprotein(a) levels: the FOURIER trial